A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma

References

• Allen TM. (1998). Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 56:747–56
   PubMed Web of Science ®Google Scholar
• Allen TM. (2004). Cullis PR. Drug delivery systems: entering the mainstream. Science 303:1818–22
   PubMed Web of Science ®Google Scholar
• Amin M, Badiee A, Jaafari MR. (2013). Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas. Int J Pharm 458:324–33
   PubMed Web of Science ®Google Scholar
• Bagri A, Tessier-Lavigne M, Watts RJ. (2009). Neuropilins in tumor biology. Clin Cancer Res 15:1860–4
   Web of Science ®Google Scholar
• Becker PM, Waltenberger J, Yachechko R, et al. (2005). Neuropilin-1 regulates vascular endothelial growth factor-mediated endothelial permeability. Circ Res 96:1257–65
   PubMed Web of Science ®Google Scholar
• Bielenberg DR, Klagsbrun M. (2007). Targeting endothelial and tumor cells with semaphorins. Cancer Metastasis Rev 26:421–31
   PubMed Web of Science ®Google Scholar
• Cairo CW, Gestwicki JE, Kanai M, et al. (2002). Control of multivalent interactions by binding epitope density. J Am Chem Soc 124:1615–9
   PubMed Web of Science ®Google Scholar
• Dunne M, Zheng J, Rosenblat J, et al. (2011). APN/CD13-targeting as a strategy to alter the tumor accumulation of liposomes. J Control Release 154:298–5
   PubMed Web of Science ®Google Scholar
• Gabizon A, Shmeeda H, Horowitz AT, et al. (2004). Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliv Rev 56:1177–92
   PubMed Web of Science ®Google Scholar
• Geretti E, Shimizu A, Klagsbrun M. (2008). Neuropilin structure governs VEGF and semaphorin binding and regulates angiogenesis. Angiogenesis 11:31–9
   PubMed Web of Science ®Google Scholar
• Graeven U, Rodeck U, Karpinski S, et al. (2000). Expression patterns of placenta growth factor in human melanocytic cell lines. J Invest Dermatol 115:118–23
   PubMed Web of Science ®Google Scholar
• Gu F, Zhang L, Teply BA, et al. (2008). Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 105:2586–91
   PubMed Web of Science ®Google Scholar
• Hood JD, Cheresh DA. (2002). Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91–100
   PubMed Web of Science ®Google Scholar
• Huo M, Zou A, Yao C, et al. (2012). Somatostatin receptor-mediated tumor-targeting drug delivery using octreotide-PEG-deoxycholic acid conjugate-modified N-deoxycholic acid-O, N-hydroxyethylation chitosan micelles. Biomaterials 33:6393–407
   PubMed Web of Science ®Google Scholar
• Jin H, Varner J. (2004). Integrins: roles in cancer development and as treatment targets. Br J Cancer 90:561–5
   PubMed Web of Science ®Google Scholar
• Kramer RH, Vu M, Cheng YF, et al. (1991). Integrin expression in malignant melanoma. Cancer Metastasis Rev 10:49–59
   PubMed Web of Science ®Google Scholar
• Lasic DD. (1996). Doxorubicin in sterically stabilized liposomes. Nature 380:561–2
   PubMed Web of Science ®Google Scholar
• Liu Y, Ji M, Wong MK, et al. (2013). Enhanced therapeutic efficacy of iRGD-conjugated crosslinked multilayer liposomes for drug delivery. Biomed Res Int 2013:378–80
   Google Scholar
• Lu Y, Wu J, Wu J, et al. (2007). Role of formulation composition in folate receptor-targeted liposomal doxorubicin delivery to acute myelogenous leukemia cells. Mol Pharm 4:707–12
   PubMed Web of Science ®Google Scholar
• Marczak A, Kowalczyk A, Wrzesień-Kus A, et al. (2006). Interaction of doxorubicin and idarubicin with red blood cells from acute myeloid leukaemia patients. Cell Biol Int 30:127–32
   PubMed Web of Science ®Google Scholar
• Minko T, Pakunlu RI, Wang Y, et al. (2006). New generation of liposomal drugs for cancer. Anticancer Agents Med Chem 6:537–52
   PubMedGoogle Scholar
• Mizejewski GJ. (1999). Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 222:124–38
   PubMed Web of Science ®Google Scholar
• Morelli D, Ménard S, Cazzaniga S, et al. (1997). Intratibial injection of an anti-doxorubicin monoclonal antibody prevents drug induced myelotoxicity in mice. Br J Cancer 75:659–9
   Google Scholar
• Nikolopoulos SN, Blaikie P, Yoshioka T, et al. (2004). Integrin beta4 signaling promotes tumor angiogenesis. Cancer Cell 6:471–83
   PubMed Web of Science ®Google Scholar
• Pellet-Many C, Frankel P, Jia H, et al. (2008). Neuropilins: structure, function and role in disease. Biochem J 411:211–26
   PubMed Web of Science ®Google Scholar
• Schädlich A, Rose C, Kuntsche J, et al. (2011). How stealthy are PEG-PLA nanoparticles? An NIR in vivo study combined with detailed size measurements. Pharm Res 28:1995–2007
   PubMed Web of Science ®Google Scholar
• Sethuraman VA, Bae YH. (2007). TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Control Release 118:216–24
   PubMed Web of Science ®Google Scholar
• Sharma P, Brown S, Walter G, et al. (2006). Nanoparticles for bioimaging. Adv Colloid Interface Sci 123–126:471–85
   PubMed Web of Science ®Google Scholar
• Silvander M. (2002). Steric stabilization of liposomes – a review. Progr Colloid Polym Sci 120:35–40
   Google Scholar
• Slingerland M, Guchelaar HJ, Gelderblom H. (2012). Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today 17:160–6
   PubMed Web of Science ®Google Scholar
• Stephenson JM, Banerjee S, Saxena NK, et al. (2002). Neuropilin-1 is differentially expressed in myoepithelial cells and vascular smooth muscle cells in preneoplastic and neoplastic human breast: a possible marker for the progression of breast cancer. Int J Cancer 101:409–14
   PubMed Web of Science ®Google Scholar
• Sugahara KN, Teesalu T, Karmali PP, et al. (2009). Tissue-penetrating delivery of compounds and nanoparticles into tumors. Cancer Cell 16:510–20
   PubMed Web of Science ®Google Scholar
• Sugahara KN, Teesalu T, Karmali PP, et al. (2010). Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 328:1031–5
   PubMed Web of Science ®Google Scholar
• Teesalu T, Sugahara KN, Ruoslahti E. (2013). Tumor-penetrating peptides. Front Oncol 27:216–23
   Google Scholar
• Wang X, Wang Y, Chen X, et al. (2009). NGR-modified micelles enhance their interaction with CD13-overexpressing tumor and endothelial cells. J Control Release 139:56–62
   PubMed Web of Science ®Google Scholar
• Waite CL, Roth CM. (2011). Binding and transport of PAMAM-RGD in a tumor spheroid model: the effect of RGD targeting ligand density. Biotechnol Bioeng 108:2999–3008
   PubMed Web of Science ®Google Scholar
• Xiang Y, Liang L, Wang X, et al. (2011). Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. J Control Release 152:402–10
   PubMed Web of Science ®Google Scholar
• Xiong XB, Huang Y, Lu WL, et al. (2005a). Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release 107:262–75
   PubMed Web of Science ®Google Scholar
• Xiong XB, Huang Y, Lu WL, et al. (2005b). Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J Pharm Sci 94:1782–93
   PubMed Web of Science ®Google Scholar
• Yang T, Wang Y, Li Z, et al. (2012). Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine. 8:81–92
   PubMed Web of Science ®Google Scholar
• Yang Z, Lei Z, Li B, et al. (2010). Rapamycin inhibits lung metastasis of B16 melanoma cells through down-regulating alpha-v integrin expression and up-regulating apoptosis signaling. Cancer Sci 101:494–500
   PubMed Web of Science ®Google Scholar
• Ye Y, Zhu L, Ma Y, et al. (2011). Synthesis and evaluation of new iRGD peptide analogs for tumor optical imaging. Bioorg Med Chem Lett 21:1146–50
   PubMed Web of Science ®Google Scholar
• Yu KF, Zhang WQ, Luo LM, et al. (2013). The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation. Int J Nanomedicine 8:2473–85
   PubMed Web of Science ®Google Scholar
• Yue J, Liu S, Wang R, et al. (2012). Transferrin-conjugated micelles: enhanced accumulation and antitumor effect for transferrin-receptor-overexpressing cancer models. Mol Pharm 9:1919–31
   PubMed Web of Science ®Google Scholar
• Zhang HT, Li HC, Li ZW, et al. (2011). A tumor-penetrating peptide modification enhances the antitumor activity of endostatin in vivo. Anticancer Drugs 22:409–15
   PubMed Web of Science ®Google Scholar
• Zhu Z, Xie C, Liu Q, et al. (2011). The effect of hydrophilic chain length and iRGD on drug delivery from poly(ɛ-caprolactone)-poly(N-vinylpyrrolidone) nanoparticles. Biomaterials 32:9525–35
   PubMed Web of Science ®Google Scholar